Alluvi, formerly BI 4744, offers a significant advance in weight management care. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates https://crossbookmark.com/story22001813/alluvi-a-in-depth-investigation-into-the-drug-s-potential